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1106-185 Growth Hormone–Releasing Peptide Can Suppress 
Myocardial Oxidative Stress and Ameliorate 
Progressive Left Ventricular Remodeling in 
Cardiomyopathic Hamsters
Mitsunori Iwase, Sahoko Ichihara, Yosuke Kato, Aya Matsushita, Hiroaki Kanazawa, 
Katsunori Hashimoto, Koji Obata, Kohzo Nagata, Toyoaki Murohara, Mitsuhiro Yokota, 
Takasi Tsunematsu, Yoshihiro Ishikawa, Nagoya University Graduate School of Medicine, 
Nagoya, Aichi, Japan, Yokohama City University, Yokohama, Kanagawa, Japan
Background: Growth hormone-releasing peptide (GHRP) may act directly on the myo-
cardium and improve left ventricular (LV) function, implicating a potential new approach
to the treatment of cardiomyopathic hearts. We hypothesized that cardiac favorable
effects of GHRPs might include the attenuation of myocardial oxidative stress.
Methods and Results: Dilated cardiomyopathic TO-2 hamsters (6 weeks old) were
injected with GHRP-2 (1mg/kg per day, n=8), or saline (n=8) for 6 weeks. F1B hamsters
served as controls (n=8). LV functional and structural changes were evaluated by
echocardiogram and the extents of myocardial oxidative stress were determined by myo-
cardial 4-hydroxy-2-noneal (HNE) concentration as well as the tissue-reduced glutathion,
oxidized glutathione, and the redox ratio (GSH/GSSG). LV fractional shortening (LVFS)
decreased from 53.0 ± 1.4 to 25.1 ± 1.0 % and the LV end-diastolic dimension increased
from 3.7 ± 0.1 to 5.0 ± 0.1 mm in untreated TO-2 hamsters between 6 and 12 weeks.
Both LVFS and LV dimension were substantially improved by treatment with GHRP-2
(41.5 ± 1.5 %, 4.6 ± 0.1 mm, respectively). The ratio of LV dimension / LV wall thickness
in untreated TO-2 hamsters was significantly greater than that in controls (6.42 ± 0.23
Versus 3.73 ± 0.13, p<0.001), and was substantially normalized by the treatment with
GHRP-2 (4.78 ± 0.23). The extent of cardiac fibrosis in TO-2 hamsters with GHRP was
significantly less than that in untreated TO-2 hamsters. The level of HNE in hearts of TO-
2 hamsters was greater than that in controls (1.63 ± 0.14 Versus 0.85 ± 0.08 pmol/mg
protein ), and was normalized by the treatment of GHRP-2 (0.71 ± 0.07 pmol/mg protein).
The redox ratio in hearts of untreated TO-2 hamsters was greater than that in controls
(2.98 ± 0.08 Versus 1.95 ± 0.04, p<0.005) and it was improved by the treatment of
GHRP-2 (2.36 ± 0.08). Myocardial glutathione peroxidase activity in untreated TO-2 ham-
sters was similar to that in F1B hamsters. Conclusion: GHRP can reduce myocardial
oxidative stress during the initial development of LV dysfunction, leading to a favorable
modification of progressive LV remodeling process in dilated cardiomyopathic hamsters.
1106-186 Testosterone Inhibits the α1C Subunit of L-Type Ca2+ 
Channels (Cav1.2) and α1H T-type Ca2+ Channels 
(Cav3.2) Stably Expressed in Human Embryonic Kidney 
293 Cells
Jason L. Scragg, Richard D. Jones, T Hugh Jones, Kevin S. Channer, Chris Peers, The 
University of Leeds, Leeds, United Kingdom, The University of Sheffield, Sheffield, 
United Kingdom
Background: Testosterone therapy reduces myocardial ischaemia in men with coronary
artery disease (CAD) [1] and improves symptom scores and exercise capacity in men
with congestive heart failure (CHF) [2]. These effects may be attributed to a direct
vasodilatory efficacy in the coronary [3] and peripheral [4] vasculature. In vitro studies
suggest this vasodilatation is due to a calcium antagonistic action upon voltage-gated
Ca2+ channels [5], but this has yet to be investigated directly. Methods: We employed
patch clamp methodology to study the effect of testosterone (1nM-1µM) upon whole-cell
Ca2+ channel currents (using 20mM Ba2+ as the charge carrier) in HEK 293 cells stably
expressing either the main pore-forming α1C subunit of a human L-type Ca2+ channel
(Cav1.2), or the α1H T-type Ca2+ channel (Cav3.2) [6]. Results: Testosterone (1nM-1µM)
caused a rapid, irreversible concentration-dependent inhibition of L-type Ca2+ currents,
with an IC50 value of 61.0±0.6nM (n = 4-9 cells at each concentration tested). Current-
voltage relationships indicated that testosterone caused a similar inhibition at all activat-
ing potentials, suggesting that the inhibition was voltage-independent. Testosterone
(1nM-1µM) also inhibited currents mediated via T-type Ca2+ channels, but this effect was
partially reversible with a lower IC50 value of 231.9±0.7nM. Conclusions: Testosterone
acts as an inhibitor of both human L-type and T-type Ca2+ channels, the major voltage-
gated calcium channels expressed in vascular smooth muscle. Inhibition of L-type Ca2+
channels occurred at physiological concentrations. This calcium antagonistic action may
contribute to the clinical benefits associated with testosterone therapy in men with CAD
and CHF.
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1106-187 Both Beta-Blockers and Amiodarone Increase Speed of 
QT / Heart Rate Adaptation
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Background: Recent studies gave evidence that the combination of amiodarone and beta
blocker (BB) treatment is beneficial. This therapeutic option may be relevant in many
areas including those of no clear indication for ICD. However, the mode of synergistic
action is still to be established. Since both substances were shown to modulate QT/RR
relationship we investigated a descriptor of QT rate adaptation speed in Holter recordings
of patients from the EMIAT database surviving the 2-year follow-up period.
Methods: In 754 (403 amiodarone, 351 placebo) 24-hour Holter recordings obtained 1
month after randomisation into EMIAT RR, and QT intervals were measured automati-
cally on a beat-to-beat basis using a commercial Holter system. The individual QT rate
adaptation profile was assessed on a continuous basis by quantifying the weighted
impact of RR interval history on each QT interval and expessing this by the so-called
lambda factor (LF). The smaller LF, the faster QT interval adaptation to heart rate.
Results were compared in patients on and off BB in the amiodarone and the placebo
group.
Results: Both amiodarone and BB increased the speed of QT adaptation to changes in
RR interval (LF: placebo vs placebo+BB, 50.4± 6.7 vs 47.4± 7.7, p=0.000006; amio-
darone vs amiodarone+BB: 47.9± 6.8 vs 43.1± 7.5, p=2× 10-11). Examples in the figure.
Conclusions: Both amiodarone and BB improve adaptation of QT interval to changes in
RR interval. This might be one of the reasons for the superior benefit of a combination of
the therapies. 
1106-188 Ghrelin Is Synthesized and Secreted by Human 
Cardiomyocytes Protecting These Cells From Apoptosis
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Background: Ghrelin, the endogenous ligand of growth hormone secretagogue receptor
(GHS-R), acts on the pituitary and the hypothalamus to stimulate the release of growth
hormone (GH) and promote appetite and adiposity. It has also been reported to increase
myocardial contractility, induce vasodilation, and protect against myocardial-infarction-
induced heart failure. Though principally gastric in origin, it is also produced by other tis-
sues. This work investigated whether cardiomyocytes synthesize and secrete ghrelin,
and how its production in these cells responds to stress and exogenous apoptotic agents.
Methods and Results. RT-PCR showed that cells of the adult mouse cardiomyocyte line
HL-1 produce mRNAs for both ghrelin and GHS-R, and competitive binding studies using
125I-labelled ghrelin showed efficient constitutive expression of GHS-R at the surface of
HL-1 cells. Immunohistochemistry confirmed the presence of ghrelin in the cytoplasm of
HL-1 cells and of isolated human cardiomyocytes in primary culture. Radioimmunoassay
showed that ghrelin was secreted by HL-1 cardiomyocytes into the culture medium.
Ghrelin did not modify the viability of HL-1 cells subjected to 12
 
h starvation, but did pro-
tect against the apoptosis inducer cytosine arabinoside (AraC). Finally, production of
ghrelin mRNA in HL-1 cardiomyocytes was reduced by AraC but increased if exposure to
AraC was preceded by GH treatment.Conclusions. We demonstrate for the first time that
ghrelin is synthesized and secreted by isolated murine and human cardiomyocytes, prob-
ably with paracrine/autocrine effects protecting these cells from apoptosis. This new axis
may play a beneficial role in myocardial dysfunction and heart failure.
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825-1 Efficacy and Safety of Ximelagatran Compared With 
Well-Controlled Warfarin in Elderly Patients With 
Nonvalvular Atrial Fibrillation: Observations From the 
SPORTIF Trials
S. Bertil Olsson, for the Executive Steering Committee on Behalf ofthe SPORTIF 
Investigators, University Hospital, Lund, Sweden, Mount Sinai Medical Center, New York, 
NY
Background: Nonvalvular atrial fibrillation (AF) affects 5-10% of people over 75 years of
age, in whom the risk of thromboembolism is higher than in younger individuals. Although
adjusted-dose warfarin protects against ischemic stroke, many patients cannot sustain
treatment because of bleeding, drug interactions, and coagulation monitoring. The oral
direct thrombin inhibitor, ximelagatran (ExantaTM, AstraZeneca), is a potential alterna-
tive anticoagulant. Both treatments were compared in patients of at least 75 years.
Methods: The SPORTIF III (open-label, n = 3410) and V (double-blind, n = 3922) trials
included 2804 patients at least 75 years of age with AF and at least 1 stroke risk factor
randomized to adjusted-dose warfarin (target INR 2.0–3.0) or fixed-dose ximelagatran
(36 mg twice daily). The primary endpoint was stroke (ischemic or hemorrhagic) and sys-
